Drug recall · July 13, 2016
Tazorac recall
Why: Failed Content Uniformity Specifications.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Tazorac (tazarotene) Gel 0.05%, Rx only, packaged in a) 30g (NDC 0023-8335-03) and b) 100g (NDC 0023-8335-10) tubes, Allergan Inc, Irvine, CA 92612
- Lots / codes
Lot #: a) 84172, b) 84173, Exp FEB/2017
- Quantity
- 17802 units
- Company
- Allergan Sales, LLC, Waco, TX
- Distribution
- Nationwide and Puerto Rico
- Initiated
- May 10, 2016 · Voluntary: Firm initiated
- Classified
- July 6, 2016
- Reported
- July 13, 2016
- Ended
- December 6, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Tazarotene
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.